BRISTOL-MYERS SQUIBB CO
BMYNYSE🏆 #100 by market capBiotech
$63.62▼ $1.22 (−1.92%)
Live1h—
24h▼ 1.9%
7d▲ 0.0%
14d▲ 0.8%
30d▲ 7.2%
1y▲ 36.7%
🏦Market Cap
$129.91B
Mid Cap
📈Revenue Growth (YoY)
+3.1%
Slowing
📊Gross Margin
71.7%
High
💵FCF Margin
33.9%
Strong
⚖️P/S Ratio
2.7x
Cheap
Otter Score
61
Fair
Trading Snapshot
- Day Range
- $62.69 – $63.89
- 52-Week Range
- $42.52 – $68.10
- Volume
- $6.25B
- Avg Volume
- $5.17B
- Shares Outstanding
- 2.04B
- Next Earnings
- Oct 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $49.10B
- Last Q Revenue
- $11.57B
- P/E Ratio
- 14.3
- P/S Ratio
- 2.7x
- EPS (TTM)
- $4.54
- Dividend Yield
- 5.71%
Why Investors Own BMY
- ✓High-growth profile — revenue up +2.6% YoY with expanding Biotech exposure.
- ✓Healthy economics — 37% gross margin and 17% free-cash-flow margin.
- ✓Deep pipeline with potential catalysts and durable IP.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$49.10B▼ −1.5% YoY
Gross Margin (TTM)
37.1%▲ +2.2% YoY
Operating Income (TTM)
$16.25B▼ −1.5% YoY
Free Cash Flow (TTM)
$8.40B▼ −1.5% YoY
About BRISTOL-MYERS SQUIBB CO
A company profile for BRISTOL-MYERS SQUIBB CO isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
61/100
Analyst Price Target
ⓘAverage Target
$72.20
▲ +13.5% Upside
High Target$83.73
Low Target$57.35
Based on 10 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
BRISTOL-MYERS SQUIBB CO tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift BMY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Barron’s·1d ago
BRISTOL-MYERS SQUIBB CO announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.